Ranking · Summer 2024 · Healthcare · Therapeutics

Evolvere BioSciences

Making Next-Generation Antibiotics that Outpace Bacterial Evolution

4.0%

odds of being acquired in the next two years

0.6× the average (6.8%)

#4087 of 4,339 active YC companies · top 95%

Team of 3 · Oxford, England, United Kingdom

Raises the odds

↑ 1.5–3 years since YC

↑ team of 3–5

Lowers the odds

↓ industry: Healthcare

↓ tag: Artificial Intelligence

↓ tag: Biotech

From the model: how this company's profile compares with companies that were and weren't acquired since 2024. How it works.

Signals brief

ExitOdds reads Evolvere BioSciences's website and YC profile; Contextrie keeps the passages that bear on an acquisition, and every signal quotes its source.

3 free briefs left today

evolverebiosciences.com YC profile

Statistical estimate from public directory data as of 2026-10-07; it can't see revenue, funding or talks. Not investment advice. ExitOdds is independent and not affiliated with Y Combinator.

Built with open source on GitHub